Cannabis News
Cannabis for Prostate Cancer – Do We Know If Weed Can Help at All?
Published
10 months agoon
By
admin
Medical marijuana is commonly utilized for addressing conditions such as chronic pain, Parkinson’s disease, multiple sclerosis, epilepsy, and Crohn’s disease. Despite being subject to research, there remains limited knowledge regarding its potential efficacy in treating cancer, specifically prostate cancer. The following insights shed light on the existing scientific understanding.
Distinguishing THC from CBD:
Marijuana comprises two primary components known as THC (tetrahydrocannabinol) and CBD (cannabidiol), collectively referred to as cannabinoids. THC induces a psychoactive high, whereas CBD does not produce such effects; instead, it imparts a calming and comfortable sensation.
Potential Application in Prostate Cancer:
Prostate cancer is conventionally treated with established methods such as testosterone blockers, radiation, surgery, and various medications. While cannabinoids have demonstrated some activity against prostate cancer in laboratory and mouse studies, their utilization for prostate cancer treatment is not advisable.
Mechanism of Action:
Cannabinoids, like other chemicals, can bind to cell receptors, influencing the behaviour of cells. Two types of receptors are associated with cannabinoids:
1. CB1: Predominantly located in the brain, these receptors contribute to the potential pain-relieving properties of marijuana.
2. CB2: Found in immune system cells, blood-forming organs, and potentially other tissues, CB2 receptors have been stimulated by scientists to exhibit anti-cancer effects on various human tumors, including brain cancer, lymphomas, and breast cancer.
Studies indicate that cannabinoids play a role in regulating cell growth and exhibit the potential to impede the development of cancer cells by diminishing their likelihood of survival, growth, dissemination, and adhesion to other cancer cells. This suggests a potential broad-spectrum application in treating various types of cancer, including prostate cancer.
Marijuana is believed to selectively target tumor cells while having minimal impact on non-tumor cells. This selectivity could render it less toxic to the body than other treatment modalities, such as chemotherapy.
Furthermore, research reveals that prostate cancer cells exhibit elevated levels of both CB1 and CB2 receptors in comparison to normal cells. This heightened presence of receptors implies a heightened affinity of cancer cells for cannabinoids compared to normal cells. Laboratory investigations demonstrate that when treated with cannabinoids, the following outcomes are observed:
1. Increased likelihood of cell death.
2. Decreased androgen receptor activity on the surface of prostate cancer cells. This is significant as prostate cancer is influenced by androgens and male hormones.
3. Inhibition of the formation of tumor blood vessels, which are essential for supplying nutrients and facilitating the growth of prostate cancer cells.
A study conducted in Spain discovered that the introduction of cannabinoids to three distinct human prostate cancer cell types resulted in a deceleration of their growth. Notably, cannabinoids specifically targeting CB2 were found to induce apoptosis, a process colloquially referred to as cell suicide, effectively eliminating prostate cancer cells.
To further investigate, researchers implanted an aggressive form of human prostate cancer cell, PC-3, into mice. The mice were divided into three groups: one receiving saline solution, another treated with a cannabinoid, and the third administered the same cannabinoid alongside a substance blocking its effects on CB2. Mice treated solely with the cannabinoid exhibited a noteworthy reduction in tumor growth compared to the other two groups.
It’s important to note that these studies exclusively focused on prostate cancer cells cultured in laboratories or within mice. No research has explored the effects of cannabinoids in humans, leaving uncertainties about whether the observed outcomes would be replicated in people. Additionally, the precise mechanisms by which cannabinoids hinder the enlargement or division of prostate cancer cells remain unclear.
Is Medical Marijuana a Viable Option for Alleviating Prostate Cancer Treatment Symptoms?
Recent research suggests that medical marijuana may provide relief for various symptoms associated with prostate cancer treatment, including:
1. Cancer-related pain: Particularly effective in conjunction with opioids, medical marijuana has shown promise in reducing severe pain signals in the brain and alleviating inflammation.
2. Neuropathy: Commonly occurring as weakness, numbness, tingling, or burning sensations in the hands or feet due to chemotherapy-induced nerve damage, cannabinoids, as indicated in animal studies, may offer relief. However, human studies yield mixed results.
3. Nausea and vomiting: FDA-approved synthetic cannabinoids, such as dronabinol and nabilone, have demonstrated efficacy in treating chemotherapy-induced nausea and vomiting. However, research on alternative forms of marijuana, such as smoking, vaping, or CBD oil, is limited.
4. Weight loss: THC, a component of marijuana, has been linked to increased appetite and slowed weight loss in individuals with advanced cancer, according to some research.
However, using medical marijuana or CBD oil with prostate cancer entails potential risks, including:
1. Loss of control over movement, disorientation, and feelings of anxiety or paranoia.**
2. Health risks associated with smoking: Since marijuana shares many substances with tobacco smoke, smoking poses health risks.
3. Unpredictability: Variability in marijuana plant strains and their active compound levels makes predicting individual responses challenging.
How to Acquire CBD and Medical Marijuana
CBD oil has become widely accessible, with products available in grocery stores and vitamin shops. Distinguished by its absence of THC, the psychoactive component of marijuana, CBD is commonly marketed as an oil but can also be found in various forms such as extracts, vaporized liquids, edibles like gummies, food items, drinks, and beauty products. It’s important to note that CBD lacks regulation by the FDA, making it challenging to determine its precise content. A study analyzing 84 CBD products revealed that over a quarter contained higher CBD levels than indicated on the label, and some even contained THC.
The sole FDA-approved medical marijuana product is a prescription oil named Epidiolex, authorised for treating epilepsy. However, there is no evidence to suggest its effectiveness in addressing prostate cancer or alleviating cancer treatment-related symptoms. Epidiolex may lead to side effects such as dry mouth, diarrhea, loss of appetite, and fatigue. Additionally, it could interact with other medications, including blood thinners. Consulting with a doctor is crucial to ensure its safe use, particularly if you have underlying medical conditions.
For those contemplating the use of medical marijuana, it is essential to check and comply with state regulations. The product can typically be obtained at a medical dispensary if legally permitted.
Bottom Line
While there is promising evidence suggesting the potential benefits of cannabinoids in addressing symptoms associated with prostate cancer treatment, the application of medical marijuana for treating cancer itself remains uncertain and not recommended based on current knowledge. The distinct roles of THC and CBD, coupled with cannabinoid receptors CB1 and CB2, provide insights into potential mechanisms, yet more research, especially in human subjects, is crucial for conclusive understanding. Caution is advised due to potential risks, and individuals considering medical marijuana should adhere to state regulations and consult with healthcare professionals to ensure safety and efficacy, especially in the absence of comprehensive FDA regulation in this realm.
WEED AND PROSTATE CANCER, READ ON…
You may like
-
Latest Trump Weed Rumor – Trump Will Federally Deschedule and Decriminalize Cannabis, but Not Legalize It
-
Webinar Replay: Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em
-
I Had Just One Puff
-
Marijuana firms Eaze, Green Dragon find new life after $10 million capital infusion
-
Get some rest on Modified Grapes—November’s Leafly HighLight
-
Is Kratom Addictive? Understanding Dependence, Risks, and Safe Usage
Cannabis News
Latest Trump Weed Rumor – Trump Will Federally Deschedule and Decriminalize Cannabis, but Not Legalize It
Published
3 hours agoon
November 14, 2024By
admin
In a recent interview, former New Jersey Governor Chris Christie made headlines by asserting that President-elect Donald Trump will pursue significant reforms in federal policies regarding marijuana and cryptocurrency. As the nation grapples with evolving attitudes toward cannabis and the burgeoning digital currency market, Christie’s predictions have ignited discussions about the potential implications of such changes on both industries. This article delves into Christie’s insights, the current state of marijuana and cryptocurrency regulations, and the broader implications of these anticipated reforms.
The Current Landscape of Marijuana Legislation
Federal vs. State Laws
Marijuana remains classified as a Schedule I substance under the Controlled Substances Act (CSA), which places it in the same category as heroin and LSD. This classification has created a complex legal landscape where states have moved to legalize cannabis for medical and recreational use, while federal law continues to impose strict prohibitions. As of now, over 30 states have legalized marijuana in some form, leading to a burgeoning industry that generates billions in revenue.
Challenges Faced by the Cannabis Industry
Despite its legality in many states, the cannabis industry faces significant hurdles due to federal restrictions. These challenges include:
-
Banking Access: Many banks are hesitant to work with cannabis businesses due to fear of federal repercussions, forcing these businesses to operate largely in cash.
-
Taxation Issues: The IRS enforces Section 280E of the tax code, which prohibits businesses engaged in illegal activities from deducting normal business expenses, leading to disproportionately high tax burdens for cannabis companies.
-
Interstate Commerce: The lack of federal legalization prevents cannabis businesses from operating across state lines, limiting their growth potential.
Chris Christie’s Perspective on Marijuana Reform
Christie, a former presidential candidate known for his tough stance on drugs during his tenure as governor, has evolved his views on marijuana over the years. In his recent statements, he emphasized that Trump is likely to pursue descheduling cannabis, which would remove it from the Schedule I classification. This move would not only provide clarity for businesses operating in legal markets but also open avenues for banking and investment.
Christie highlighted that descheduling would allow for a more regulated market where safety standards could be established, thus protecting consumers. He believes that this approach aligns with a growing consensus among Americans who support legalization and recognize the potential benefits of cannabis use for both medical and recreational purposes.
The Future of Cryptocurrency Regulation = The Rise of Cryptocurrencies
Cryptocurrencies have surged in popularity over the past decade, with Bitcoin leading the charge as the first decentralized digital currency. The market has expanded to include thousands of alternative coins (altcoins), each with unique features and use cases. As cryptocurrencies gain traction among investors and consumers alike, regulatory scrutiny has intensified.
Current Regulatory Challenges
The cryptocurrency market faces several regulatory challenges that hinder its growth and adoption:
-
Lack of Clarity: Regulatory frameworks vary significantly across states and countries, creating confusion for investors and businesses.
-
Fraud and Scams: The rapid growth of cryptocurrencies has led to an increase in fraudulent schemes targeting unsuspecting investors.
-
Consumer Protection: Without clear regulations, consumers are often left vulnerable to risks associated with volatile markets.
Christie’s Vision for Crypto Regulation
Christie believes that under Trump’s leadership, there will be an effort to find a “sweet spot” for cryptocurrency regulation balancing innovation with consumer protection. He argues that overly stringent regulations could stifle growth in this emerging sector while too little oversight could expose consumers to significant risks.
In his view, a balanced regulatory framework would include:
1. Clear Definitions: Establishing clear definitions for different types of cryptocurrencies and tokens to differentiate between securities and utility tokens.
2. Consumer Protections: Implementing measures to protect investors from fraud while promoting transparency within the market.
3. Encouraging Innovation: Creating an environment conducive to innovation by allowing startups to thrive without excessive regulatory burdens.
Christie’s insights reflect a growing recognition among policymakers that cryptocurrencies are here to stay and that appropriate regulations are necessary to foster growth while safeguarding consumers.
Implications of Proposed Reforms
Economic Impact
The potential reforms proposed by Christie could have far-reaching economic implications:
-
Job Creation: Legalizing marijuana at the federal level could lead to significant job creation within the cannabis industry—from cultivation and production to retail sales.
-
Investment Opportunities: Descheduling cannabis would open up investment opportunities for institutional investors who have been hesitant due to federal restrictions.
-
Boosting Local Economies: Legal cannabis markets have proven beneficial for local economies through increased tax revenues and job creation.
Similarly, clear regulations around cryptocurrencies could stimulate investment in blockchain technology and related industries, fostering innovation and economic growth.
Social Justice Considerations
Both marijuana legalization and sensible cryptocurrency regulations have social justice implications:
-
Addressing Past Injustices: Legalizing marijuana could help rectify past injustices related to drug enforcement policies that disproportionately affected marginalized communities.
-
Financial Inclusion: Cryptocurrencies offer opportunities for financial inclusion for those underserved by traditional banking systems, particularly in low-income communities.
Political Landscape
The political landscape surrounding these issues is complex. While there is bipartisan support for marijuana reform among certain lawmakers, challenges remain in overcoming entrenched opposition. Similarly, cryptocurrency regulation has garnered attention from both sides of the aisle but requires collaboration to establish effective frameworks.
Conclusion
Chris Christie’s predictions about President-elect Donald Trump’s approach to federal marijuana descheduling and cryptocurrency regulation suggest a potential shift in U.S. policy that could significantly reshape both industries. As public opinion evolves on these issues, lawmakers have an opportunity to enact meaningful reforms that promote economic growth while ensuring consumer protection. The anticipated changes could foster a more robust cannabis industry that contributes positively to the economy and addresses social justice concerns, while clear regulatory frameworks for cryptocurrencies could encourage innovation and protect consumers in the digital economy. Stakeholders in both sectors are closely watching these developments, eager to see how potential reforms might impact their futures. While the realization of Christie’s predictions remains uncertain, it’s clear that the conversation around marijuana and cryptocurrency regulation is ongoing and far from settled.
TRUMP 2.0 ON CANNABIS REFORM, READ ON…
TRUMP 2.0 ON FEDERAL CANNABIS REFORM – WHAT DO WE KNOW?
Cannabis News
Webinar Replay: Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em
Published
1 day agoon
November 13, 2024By
admin
On Thursday, November 7th, Vince Sliwoski, Aaron Pelley and Fred Rocafort held a post election discussion “Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em”. Watch the replay!
Key Takeaways from the “Smoke ’em if You’ve Got ’em – 2024 Post Election Cannabis Wrap” Webinar:
- Panelists:
- Vince Sliwoski: Oregon Business lawyer specializing in cannabis and commercial real estate.
- Aaron Pelley: Experienced in cannabis law since Washington’s legalization in 2012.
- Fred Rocafort: Trademark attorney working closely with the cannabis team.
- Election Results Overview:
- Most 2024 cannabis ballot measures did not pass.
- Florida, South Dakota, and North Dakota saw failures.
- Nebraska became the 39th state to legalize cannabis for medical use when it passed two cannabis initiatives, Initiatives 437 and 438.
- Federal and State-Level Developments:
- Medical use is currently legal in 38 states, and 24 states allow recreational use.
- Republican support for marijuana legalization is growing.
- Federal Policy Implications:
- Schedule III Rescheduling: The process to move cannabis to Schedule III is ongoing, which could significantly impact the industry.
- Importance of Federal Appointments: The future of cannabis policy depends heavily on who is appointed to key positions in the administration.
- International and Domestic Trade:
- Schedule III status could ease import/export restrictions on cannabis.
- Unified control of House, Senate, and presidency might expedite legislative progress.
- Economic and Industry Impact:
- Cannabis stocks experienced volatility post-election, reflecting investor uncertainty.
- Federal legalization and banking reforms are crucial for industry stability and growth.
- Future Outlook:
- The potential for federal rescheduling remains strong, with hearings scheduled for early 2025.
- State-level initiatives and regulatory developments will continue to shape the industry.
“How Long Does One Puff of Weed Stay in Your System?”… This topic can be difficult to answer since it is dependent on elements such as the size of the hit and what constitutes a “one hit.” If you take a large bong pull then cough, it might linger in your system for 5-7 days. A moderate dose from a joint can last 3-5 days, whereas a few hits from a vaporizer may last 1-3 days.
The length of time that marijuana stays in the body varies based on a number of factors, including metabolism, THC levels, frequency of use, and hydration.
Delta-9-tetrahydrocannabinol, or THC, is the primary psychoactive component of cannabis. THC and its metabolites, which remain in your body long after the effects have subsided, are detected by drug tests.
Since these metabolites are fat-soluble, they cling to bodily fat molecules. They could thus take a while to fully pass through your system, particularly if your body fat percentage is higher.
THC is absorbed by tissues and organs (including the brain, heart, and fat) and converted by the liver into chemicals such as 11-hydroxy-THC and carboxy-THC. Cannabis is eliminated in feces at a rate of around 65%, while urine accounts for 20%. The leftover amount might be kept within the body.
THC deposited in bodily tissues ultimately re-enters the circulation and is processed by the liver. For frequent users, THC accumulates in fatty tissues quicker than it can be removed, thus it may be detectable in drug tests for days or weeks following consumption.
The detection time varies according to the amount and frequency of cannabis usage. Higher dosages and regular usage result in longer detection times.
The type of drug test also affects detection windows. Blood and saliva tests typically detect cannabis metabolites for shorter periods, while urine and hair samples can reveal use for weeks or even months. In some cases, hair tests have detected cannabis use over 90 days after consumption.
Detection Windows for Various Cannabis Drug Tests
Urine Tests
Among all drug tests, urine testing is the most commonly used method for screening for drug use in an individual.
Detection times vary, but a 2017 review suggests the following windows for cannabis in urine after last use:
– Single-use (e.g., one joint): up to 3 days
– Moderate use (around 4 times a week): 5–7 days
– Chronic use (daily): 10–15 days
– Chronic heavy use (multiple times daily): over 30 days
Blood Tests
Blood tests generally detect recent cannabis use, typically within 2–12 hours after consumption. However, in cases of heavy use, cannabis has been detected up to 30 days later. Chronic heavy use can extend the detection period in the bloodstream.
Saliva Tests
THC can enter saliva through secondhand cannabis smoke, but THC metabolites are only present if you’ve personally smoked or ingested cannabis.
Saliva testing has a short detection window and can sometimes identify cannabis use on the same day. A 2020 review found that THC was detectable in the saliva of frequent users for up to 72 hours after use, and it may remain in saliva longer than in blood following recent use.
In areas where cannabis is illegal, saliva testing is often used for roadside screenings.
Hair Tests
Hair follicle tests can detect cannabis use for up to 90 days. After use, cannabinoids reach the hair follicles through small blood vessels and from sebum and sweat surrounding the hair.
Hair grows at approximately 0.5 inches per month, so a 1.5-inch segment of hair close to the scalp can reveal cannabis use over the past three months.
Factors Affecting THC and Metabolite Retention
The length of time THC and its metabolites stay in your system depends on various factors. Some, like body mass index (BMI) and metabolic rate, relate to individual body processing, not the drug itself.
Other factors are specific to cannabis use, including:
– Dosage: How much you consume
– Frequency: How often you use cannabis
– Method of consumption: Smoking, dabbing, edibles, or sublingual
– THC potency: Higher potency can extend detection time
Higher doses and more frequent use generally extend THC retention. Cannabis consumed orally may remain in the system slightly longer than smoked cannabis, and stronger cannabis strains, higher in THC, may also stay detectable for a longer period.
How Quickly Do the Effects of Cannabis Set In?
When smoking cannabis, effects appear almost immediately, while ingested cannabis may take 1–3 hours to peak.
The psychoactive component THC produces a “high” with common effects such as:
– Altered senses, including perception of time
– Mood changes
– Difficulty with thinking and problem-solving
– Impaired memory
Other short-term effects can include:
– Anxiety and confusion
– Decreased coordination
– Dry mouth and eyes
– Nausea or lightheadedness
– Trouble focusing
– Increased appetite
– Rapid heart rate
– Restlessness and sleepiness
In rare cases, high doses may lead to hallucinations, delusions, or acute psychosis.
Regular cannabis use may have additional mental and physical effects. While research is ongoing, cannabis use may increase the risk of:
– Cognitive issues like memory loss
– Cardiovascular problems including heart disease and stroke
– Respiratory illnesses such as bronchitis or lung infections
– Mood disorders like depression and anxiety
Cannabis use during pregnancy can negatively impact fetal growth and development.
Duration of Effects
Short-term effects generally taper off within 1–3 hours, but for chronic users, some long-term effects may last days, weeks, or even months. Certain effects may even be permanent.
Bottom Line
The amount of time that cannabis remains in your system following a single use varies greatly depending on individual characteristics such as body fat, metabolism, frequency of use, and mode of intake. Frequent users may maintain traces of THC for weeks, whereas infrequent users may test positive for as little as a few days. Hair tests can disclose usage for up to 90 days, while blood and saliva tests identify more recent use. Urine tests are the most popular and have varying detection durations. The duration that THC and its metabolites are detectable will ultimately depend on a number of factors, including dose, strength, and individual body chemistry.
PEE IN A CUP COMING UP, READ ON..
Latest Trump Weed Rumor – Trump Will Federally Deschedule and Decriminalize Cannabis, but Not Legalize It
Webinar Replay: Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em
I Had Just One Puff
Marijuana firms Eaze, Green Dragon find new life after $10 million capital infusion
Get some rest on Modified Grapes—November’s Leafly HighLight
Is Kratom Addictive? Understanding Dependence, Risks, and Safe Usage
New Rule, December 5: Oregon Cannabis Retailers, Processors and Labor Peace Agreements
The CBD Dog Treat Guide
Trippin’ Golf Balls – Can Magic Mushrooms Help Your Golf Game?
Australian Broadcasting Corp Alleges Military Veterans Have Been Targeted By Medicinal Cannabis Companies Via Social Media & Offered Free “Product”
Distressed Cannabis Business Takeaways – Canna Law Blog™
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
What you Need to Know
Drug Testing for Marijuana – The Joint Blog
NCIA Write About Their Equity Scholarship Program
It has been a wild news week – here’s how CBD and weed can help you relax
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
A new April 20 cannabis contest includes a $40,000 purse
Your Go-To Source for Cannabis Logos and Designs
UArizona launches online cannabis compliance online course
Trending
-
Cannabis News2 years ago
Distressed Cannabis Business Takeaways – Canna Law Blog™
-
One-Hit Wonders2 years ago
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
-
Cannabis 1012 years ago
What you Need to Know
-
drug testing11 months ago
Drug Testing for Marijuana – The Joint Blog
-
Education2 years ago
NCIA Write About Their Equity Scholarship Program
-
Cannabis2 years ago
It has been a wild news week – here’s how CBD and weed can help you relax
-
Marijuana Business Daily2 years ago
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
-
California2 years ago
A new April 20 cannabis contest includes a $40,000 purse